<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03674060</url>
  </required_header>
  <id_info>
    <org_study_id>SYO-1644</org_study_id>
    <nct_id>NCT03674060</nct_id>
  </id_info>
  <brief_title>Study to Compare Pharmacokinetic Property of SYO-1644 Tab. and Nexavar Tab. in Healthy Male Volunteers</brief_title>
  <official_title>A Dose-block Randomized, Active-controlled, Open-label Clinical Study to Compare Pharmacokinetic Property of SYO-1644 Tab and Nexavar Tab in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samyang Biopharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samyang Biopharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics characteristics ,tolerability,
      and safety after orally administrating SYO-1644 to healthy male volunteers in randomized,
      active-controlled, open-label clinical study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After orally administrating SYO-1644 and Nexavar 200 mg to healthy male participants , the
      safety, tolerability, and pharmacokinetic characteristics are to be compared while testing
      pharmacokinetic characteristics based on the dosage.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2018</start_date>
  <completion_date type="Actual">July 23, 2019</completion_date>
  <primary_completion_date type="Actual">February 8, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of pharmacokinetic properties</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 168 hours</time_frame>
    <description>Pharmacokinetics of the AUCt between SYO-1644 and Nexavar cap(200mg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of pharmacokinetic properties</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 168 hours</time_frame>
    <description>Pharmacokinetics of the Cmax between SYO-1644 and Nexavar cap(200mg)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy, Male</condition>
  <arm_group>
    <arm_group_label>SYO-1644 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SYO-1644 tablet, PO, 1 100mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYO-1644 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYO-1644 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SYO-1644 tablet, PO, 2 100mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nexavar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nexavar 200mg/tablet, PO, 1 tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYO-1644</intervention_name>
    <description>100mg: SYO-1644 tablet, PO, 1 100mg tablet
150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet
200mg: SYO-1644 tablet, PO, 2 100mg tablet</description>
    <arm_group_label>SYO-1644 100mg</arm_group_label>
    <arm_group_label>SYO-1644 150mg</arm_group_label>
    <arm_group_label>SYO-1644 200mg</arm_group_label>
    <other_name>SYO-1644 100, 150, 200mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexavar tab</intervention_name>
    <description>Nexavar 200mg/tablet, PO, 1 tablet</description>
    <arm_group_label>Nexavar</arm_group_label>
    <other_name>Sorafenib 200mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male age between 19 and 50 years old at the time of screening

          2. Healthy male more than or equal to 50 kg or less than or equal to 90 kg with BMI of
             18~27

               -  BMI(kg/m2) = Weight(kg) / {Height(m)}2

          3. Agreement with written informed consent

        Exclusion Criteria:

          1. Participants with clinically significant liver, kidney, nervous system, respiratory,
             endocrine, hematologic, cardiovascular, urinary, psychiatric disorders or history

          2. Participants with history of gastrointestinal ulcers, gastritis, gastric ulcer,
             gastroesophageal reflux disease, Crohn's disease, etc, that may affect the safety and
             pharmacokinetic evaluation of the test drug, except simple appendectomy and hernia
             surgery)

          3. Participants with hypersensitivity reactions or clinically significant
             hypersensitivity reactions to drugs including sorafenib and allogeneic drugs, and
             other drugs (aspirin, antibiotics, etc.)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 9, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Male Volunteers</keyword>
  <keyword>Evaluation of the Pharmacokinetic Property</keyword>
  <keyword>A Dose-block Randomized, Active-controlled, Open-label</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

